TITLE

Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate?

AUTHOR(S)
Philbrick, Ann M.; Ernst, Michael E.; McDanel, Deanna L.; Ross, Mary B.; Moores, Kevin G.
PUB. DATE
November 2009
SOURCE
American Journal of Health-System Pharmacy;11/15/2009, Vol. 66 Issue 22, p2017
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The relationship among metformin use, plasma lactate levels, and lactic acidosis in patients with type 2 diabetes mellitus and the appropriateness of metformin use in patients with renal dysfunction are discussed. Summary. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes recommends metformin therapy as first-line therapy along with lifestyle modification to treat type 2 diabetes mellitus. Despite this recommendation, metformin may be underutilized due to the fear of metformin-associated lactic acidosis and because its use is contraindicated in patients with renal dysfunction. Several studies have attempted to characterize the relationship among plasma metformin levels, plasma lactate levels, and lactic acidosis. However, a causal relationship between metformin and lactic acidosis has not been definitively established. In the United States, the estimated rate of lactic acidosis among diabetic patients treated with metformin is similar to that of diabetic patients not taking metformin. Despite specific guidelines advising against prescribing metformin in renal dysfunction, published reports indicate that metformin is continued in 25% of patients after the contraindication is discovered. Individual studies point to a possible correlation between metformin levels and plasma lactate levels, but mortality does not appear to correlate with plasma metformin levels. These results indicate that there may not be a direct relationship between plasma lactate and metformin levels. Conclusion. Current studies point to a weak causal relationship between metformin and lactic acidosis. In patients without comorbid conditions that would predispose them to lactic acidosis, elevated serum creatinine levels should be considered a risk factor for the development of lactic acidosis but not an absolute contraindication.
ACCESSION #
47609207

 

Related Articles

  • METFORMIN, CHRONIC KIDNEY DISEASE, AND LACTIC ACIDOSIS: IS METFORMIN ABSOLUTELY CONTRAINDICATED? McCloskey, M. C.; Smyth, J.; Marshall, W.; Leonard, N. // Ulster Medical Journal;2009, Vol. 78 Issue 1, p60 

    Aims: The UK prospective diabetes study showed that metformin was associated with a lower mortality from cardiovascular disease than sulphonylureas or insulin in obese patients with type 2 diabetes mellitus, as well as reduced all cause mortality. However, concerns remain about its side effects,...

  • Oral glucose lowering agents. Gadsby, Roger // Practice Nurse;2/27/2009, Vol. 37 Issue 4, p20 

    The article offers information on the different classes of glucose lowering agent and explains where in the treatment options they are recommended for use. The mechanism of action of sulphonylureas and mode of prescription are explained in detail. Noted side effects of metformin are lactic...

  • Fibrates and estimated glomerular filtration rate: observations from an outpatient clinic setting and clinical implications. Ahmed Abbas; Sanjay Saraf; Shanath Ramachandran; Jessie Raju; Sudarshan Ramachandran // Postgraduate Medical Journal;Sep2012, Vol. 88 Issue 1043, p503 

    BackgroundPrevious studies have demonstrated that fibrates have an effect on creatinine concentrations. The pattern of change with fibrates in estimated glomerular filtration rate (eGFR), widely used in clinical practice, has not been previously described.MethodsData was retrospectively...

  • Acalypha fruticosa, Hypoglycaemic activity, Fasting blood glucose, Metformin, Acute toxicity. Haiying Zhang; Ning Li; Kun Li; Peng Li // Tropical Journal of Pharmaceutical Research;Aug2015, Vol. 14 Issue 8, p1451 

    Purpose: To investigate the mechanism of action by which ethanol root extract of Equisetum arvense influences urinary bladder activity in rats, and to characterize the major compounds of the extract. Methods: Ethanol (95 %) was used for hot extraction for 3 h in a Soxhlet extraction apparatus. A...

  • Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Nov2008, Vol. 31 Issue 11, p2086 

    OBJECTIVE -- Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs. RESEARCH DESIGN AND...

  • Haemoglobin A1c Goal Attainment in Relation to Dose in Patients with Diabetes Mellitus Taking Metformin. Penning-van Beest, Fernie J. A.; Wolffenbuttel, Bruce H. R.; Herings, Ron M. C. // Clinical Drug Investigation;2008, Vol. 28 Issue 8, p487 

    Background and objective: Conclusions from clinical trials suggest possible therapeutic advantages for once-daily agents over twice-daily agents in the treatment of type 2 diabetes mellitus. This study set out to investigate the relationship between metformin dosing frequency and glycosylated...

  • Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Sang-hoon Jung; Jung-woo Chae; Byung-jeong Song; Kwang-il Kwon // Iranian Journal of Pharmaceutical Research;Spring2014, Vol. 13 Issue 2, p365 

    Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities...

  • Mechanism of Metformin: A Tale of Two Sites. Ruisheng Song; Song, Ruisheng // Diabetes Care;Feb2016, Vol. 39 Issue 2, p187 

    The author discusses research on the gut effect of metformin. He references the study "The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-Term Pharmacokinetic and 12-Week Dose-Ranging Studies" published in the current issue of the...

  • Simultaneous estimation of pioglitazone and metformin hydrochloride in tablet dosage form along with invitro studies. Sayed, Sadaf; Thomas, Asha // Journal of Pharmacy Research;Sep2009, Vol. 2 Issue 9, p1485 

    A simple, accurate and economic Simultaneous equation method has been described for the simultaneous determination of metformin and pioglitazone in tablet dosage formulations. Metformin and pioglitazone showed absorption maxima at 233.5 nm and 266.5 nm respectively in 0.1 M NaOH prepared in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics